Eczema

Disclaimer: This clinical reference provides general medical information for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's specific circumstances, current evidence, and local guidelines. The information herein is subject to change as medical knowledge evolves.

Overview

• Definition: Eczema, also known as dermatitis, is a general term for a group of inflammatory skin conditions characterized by pruritus (itching), erythema (redness), and often a rash that can be acute (vesicles, weeping, crusting) or chronic (lichenification, scaling). The most common and well-studied type is Atopic Dermatitis (AD), a chronic, relapsing inflammatory skin condition associated with a personal or family history of other atopic diseases (asthma, allergic rhinitis, food allergy).
• Epidemiology:
  • Atopic Dermatitis (AD): Highly prevalent, affecting 15-20% of children and 1-3% of adults globally. The prevalence has increased in recent decades, particularly in industrialized countries.
  • Age of Onset: AD typically begins in infancy or early childhood (60% by age 1, 85% by age 5).
  • Gender: No significant gender predominance, though some studies suggest slight female predominance in adults.
  • Racial/Ethnic Differences: Appears to be more prevalent and severe in certain ethnic groups (e.g., African Americans, Asian Americans).
  • Socioeconomic Status: Mixed findings, but some evidence suggests higher prevalence in higher socioeconomic groups in developing countries, while in developed countries, it may be associated with lower socioeconomic status.
• Classification: Eczema encompasses various types, each with distinct features:
  • Atopic Dermatitis (AD): The most common type, linked to atopy.
  • Contact Dermatitis:
    • Irritant Contact Dermatitis (ICD): Caused by direct skin irritation from chemicals, solvents, prolonged water exposure.
    • Allergic Contact Dermatitis (ACD): Type IV hypersensitivity reaction to specific allergens (e.g., nickel, poison ivy, fragrances).
  • Nummular Eczema (Discoid Eczema): Characterized by coin-shaped (discoid) patches of inflamed, itchy skin. Often seen in middle-aged to older adults, more common in men.
  • Dyshidrotic Eczema (Pompholyx): Presents with small, clear, itchy blisters (vesicles) on the palms, soles, and sides of fingers and toes.
  • Seborrheic Dermatitis: Chronic inflammatory condition primarily affecting sebum-rich areas (scalp, face, chest) with greasy scales and erythema. Caused by an inflammatory reaction to Malassezia yeast.
  • Stasis Dermatitis: Occurs on the lower legs due to chronic venous insufficiency, leading to edema, hyperpigmentation, scaling, and itching.
  • Asteatotic Eczema (Eczema Craquelé): Dry, cracked, "crazy paving" appearance, typically on the lower legs of elderly individuals in dry climates.
  • Neurodermatitis (Lichen Simplex Chronicus): Localized patch of thickened, intensely itchy skin resulting from repetitive scratching and rubbing.

Pathophysiology

• Mechanism: The pathophysiology of AD is multifactorial, involving a complex interplay of genetic predisposition, skin barrier dysfunction, immune dysregulation, and environmental factors.
  • Skin Barrier Dysfunction: A primary defect, often linked to mutations in the FLG gene (encoding filaggrin), a structural protein crucial for epidermal differentiation and skin hydration. This leads to increased transepidermal water loss (TEWL), reduced epidermal hydration, and impaired barrier function, allowing easier penetration of irritants, allergens, and microbes.
  • Immune Dysregulation: Predominantly a T helper type 2 (Th2) cell-mediated inflammatory response. Elevated levels of Th2 cytokines (e.g., IL-4, IL-13, IL-31) contribute to IgE overproduction, eosinophilia, and pruritus. In chronic lesions, a Th1 response (IL-12, IFN-gamma) can also be present.
  • Microbiome Dysbiosis: Altered skin microbiome (e.g., increased Staphylococcus aureus colonization and reduced diversity) contributes to inflammation and barrier disruption. S. aureus can produce superantigens that exacerbate inflammation.
  • Pruritus-Scratch Cycle: Intense itching leads to scratching, which further damages the skin barrier, promotes inflammation, and perpetuates the cycle. Neuronal sensitization and neuropeptide release contribute to chronic itch.
• Risk Factors:
  • Genetic Predisposition: Strong family history of atopic diseases (AD, asthma, allergic rhinitis). FLG gene mutations are a significant risk factor, especially for severe AD.
  • Environmental Factors:
    • Early-life allergen exposure: Certain allergens (e.g., house dust mites, pet dander, pollen) can trigger flares.
    • Irritants: Soaps, detergents, solvents, perfumes, harsh fabrics (wool).
    • Climate: Dry, cold climates can exacerbate skin dryness.
    • Pollution: Exposure to air pollutants.
    • Stress: Psychological stress can trigger or worsen flares.
    • Diet: While less common in AD generally, specific food allergies can trigger flares in a subset of children, especially those with early-onset, severe AD.
• Protective Factors:
  • Early and consistent emollient use: Regular application of moisturizers from birth, especially in high-risk infants, may reduce AD incidence.
  • Breastfeeding: Some evidence suggests a protective effect, but findings are mixed.
  • "Farm environment" exposure: Early life exposure to diverse microbes and endotoxins (e.g., living on a farm) has been associated with a reduced risk of atopy (Hygiene Hypothesis).
  • Specific nutritional factors: Limited evidence, but some studies explore probiotics or fatty acid supplementation, though not consistently recommended for prevention.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pruritus (Itching): The most prominent and often debilitating symptom, typically worse at night.
  • Erythema: Redness of the skin.
  • Xerosis (Dry Skin): Common underlying feature, contributing to barrier dysfunction.
  • Eczematous Lesions: Characterized by age-dependent morphology and distribution.
• Early Signs (Infantile Eczema, typically 0-2 years):
  • Acute Lesions: Erythematous, weeping, papulovesicular (small bumps and blisters) lesions.
  • Distribution: Often on the scalp ("cradle cap" may precede), face (cheeks, forehead), and extensor surfaces of limbs. Diaper area is usually spared.
  • Pruritus: Manifests as restlessness, rubbing, and difficulty sleeping.
• Advanced Signs (Childhood Eczema, typically 2-12 years; Adult Eczema, >12 years):
  • Subacute/Chronic Lesions: Erythema, dry scaling, papules, excoriations (scratch marks), and lichenification (skin thickening with exaggerated skin markings due to chronic scratching/rubbing).
  • Distribution:
    • Childhood: Flexural areas (antecubital and popliteal fossae), neck, wrists, ankles.
    • Adult: Similar flexural areas, but can also involve face (especially periorbital), neck, hands, and feet. Generalized erythroderma can occur in severe cases.
  • Pruritus: Severe, persistent, leading to sleep disturbance, impaired concentration, and significant impact on quality of life.
• Atypical Presentations:
  • Nummular Eczema: Coin-shaped, intensely pruritic plaques, often on limbs.
  • Dyshidrotic Eczema: Vesicles/bullae on palms and soles, often with severe pruritus.
  • Asteatotic Eczema: Dry, fissured skin ("cracked porcelain" appearance), common on shins of older adults.
  • Perioral/Periorbital Eczema: Eczema localized around the mouth or eyes, can be a challenge.
  • Hand Eczema: Chronic, recurrent, often severe and debilitating, especially common in occupations involving frequent hand washing or contact with irritants/allergens.

Physical Examination

• Inspection:
  • Skin Lesions: Varies by age and activity (acute vs. chronic).
    • Acute: Erythema, edema, papules, vesicles, bullae, serous exudate (weeping), crusting.
    • Chronic: Lichenification, excoriations, scaling, hyperpigmentation (especially in skin of color) or hypopigmentation (post-inflammatory), follicular prominence (follicular eczema).
  • Distribution: Characteristic patterns (flexural, extensor, facial, scalp) depending on age.
  • Signs of Infection: Pustules, yellow crusting (impetiginization), erosions, signs of herpes simplex infection (grouped vesicles, "punched-out" erosions, monomorphic papules).
  • Other Stigmata of Atopy:
    • Dennie-Morgan folds: Infraorbital folds.
    • Allergic shiners: Dark circles under the eyes.
    • Pallor of the face: Especially around the mouth.
    • Pityriasis alba: Hypopigmented, slightly scaly patches, often on face, neck, arms.
    • Cheilitis: Inflammation of the lips.
    • Hyperlinear palms: Increased palm creases.
    • Keratosis pilaris: Small, pointed follicular papules, especially on extensor arms/thighs.
• Palpation:
  • Skin Texture: Dry, rough, thickened (lichenified).
  • Temperature: Affected areas may feel warmer due to inflammation.
  • Tenderness: May be present if secondary infection or deep fissures.
• Special Tests:
  • Scratch test/Prick test/Patch test: Not for diagnosing AD itself, but helpful in identifying specific triggers for allergic contact dermatitis or for food/environmental allergens that may exacerbate AD.
    • Patch Testing: Gold standard for diagnosing allergic contact dermatitis.
    • Prick Testing: For IgE-mediated allergies.

Diagnostic Approach

History Taking

• Key Questions: The diagnosis of AD is primarily clinical, based on a combination of characteristic symptoms and signs. Standardized diagnostic criteria (e.g., Hanifin and Rajka criteria or UK Working Party criteria for AD) are often used in research but less strictly in clinical practice.
  • Core criteria (UK Working Party Criteria):
    1. Itchy skin condition (or parental report of scratching/rubbing in a child).
    2. PLUS three or more of the following:
       • History of involvement of skin creases (flexural dermatitis, or cheeks/extensors in infants).
       • History of asthma or allergic rhinitis (or history in first-degree relative in children <4 years).
       • History of generally dry skin in the last 12 months.
       • Visible flexural eczema (or eczema on cheeks/extensor surfaces in infants).
       • Onset of AD in a child aged <2 years (this criterion should not be used for children under 4 years).
  • Onset: When did the rash first appear? How has it evolved?
  • Course: Is it chronic and relapsing? What triggers flares? What makes it better or worse?
  • Pruritus: Severity, impact on sleep and daily activities, what relieves it?
  • Previous Treatments: What has been tried? Efficacy? Side effects?
  • Personal Atopic History: History of asthma, allergic rhinitis, food allergies, urticaria.
  • Family Atopic History: Any immediate family members with AD, asthma, or allergic rhinitis?
  • Environmental Exposures: Occupation, hobbies, pets, skincare products, detergents, new clothing.
  • Psychosocial Impact: Impact on school, work, social life, emotional well-being.
• Red Flags:
  • Sudden onset of widespread, painful, or tender vesicles/erosions: Suggests eczema herpeticum (a dermatological emergency).
  • Rapidly spreading erythema, pustules, fever, malaise: Suggests bacterial superinfection (e.g., cellulitis, impetigo).
  • Generalized erythroderma: Diffuse redness and scaling covering >90% of body surface area, can indicate severe systemic illness or widespread AD, requires urgent assessment.
  • Unusual morphology or distribution not fitting typical eczema patterns: May suggest an alternative diagnosis (e.g., cutaneous T-cell lymphoma, psoriasis, scabies).
  • Failure to respond to appropriate first-line therapy: Warrants reconsideration of diagnosis or severity assessment.

Laboratory Tests

• First-Line:
  • Generally not required for diagnosis of AD. Diagnosis is clinical.
  • Swab for Bacterial Culture and Sensitivity: If signs of secondary bacterial infection (crusting, weeping, pustules, cellulitis) are present. Common pathogens: Staphylococcus aureus (including MRSA) and Streptococcus pyogenes.
  • Viral Swab (PCR or Tzanck smear): If suspecting eczema herpeticum (HSV) or eczema coxsackium.
• Confirmatory:
  • Biopsy: Rarely needed for typical AD. May be considered if diagnosis is uncertain, to rule out other conditions (e.g., cutaneous T-cell lymphoma, psoriasis), or in atypical/refractory cases. Histopathology shows spongiosis (epidermal edema), lymphocytic infiltrate, and epidermal hyperplasia.
  • Allergen-specific IgE (RAST/ImmunoCAP) or Skin Prick Tests: Can identify sensitization to specific aeroallergens or food allergens. Note: Positive tests indicate sensitization, not necessarily clinical allergy or causation of eczema flares. Clinical correlation is essential. Not routinely performed unless there's a clear history linking exposure to flares.
  • Patch Testing: Gold standard for identifying specific contact allergens in suspected allergic contact dermatitis.
• Monitoring:
  • ESR/CRP: Rarely used, only if systemic infection is suspected.
  • Serum IgE levels: Often elevated in AD, but not diagnostic, as levels can be normal and elevated in other conditions. Not routinely monitored.
  • Complete Blood Count (CBC): May show eosinophilia, but not specific for AD.
  • Renal/Liver Function Tests: If using systemic immunosuppressants (e.g., cyclosporine, methotrexate, azathioprine) or some JAK inhibitors, for baseline and monitoring.

Imaging

• Recommended: No imaging studies are typically recommended or required for the diagnosis or routine management of eczema.
• Advanced: In rare, complex cases where systemic comorbidities are suspected, or for research purposes, advanced imaging might be used, but this is not standard clinical practice for eczema itself.

Management

The goal of eczema management is to control symptoms, reduce flare frequency, prevent complications, and improve quality of life. A stepwise approach based on severity is typically employed.

Acute Management (Flare Management)

• Immediate (within hours to days):
  • Identify and eliminate triggers: Remove irritants (harsh soaps, detergents), allergens if identified, reduce stress.
  • Topical Corticosteroids (TCS): Cornerstone of acute flare management. Potency depends on severity, age, and body area.
    • Mild to Moderate Flare:
      • Face/Intertriginous areas/Infants: Low-potency (e.g., hydrocortisone 1% cream/ointment BID-TID for 7-14 days).
      • Body/Children: Mid-potency (e.g., triamcinolone acetonide 0.1% cream/ointment BID for 7-14 days).
    • Moderate to Severe Flare:
      • Body/Adults: High-potency (e.g., fluocinonide 0.05%, clobetasol propionate 0.05% cream/ointment daily or BID for 1-2 weeks, short bursts only, avoid on face/thin skin).
  • Emollients: Apply generously and frequently (multiple times daily) immediately after bathing and throughout the day. Crucial for skin barrier repair.
  • Antipruritics:
    • Oral Antihistamines: Non-sedating antihistamines (e.g., loratadine, fexofenadine, cetirizine) for daytime symptom relief. Sedating antihistamines (e.g., diphenhydramine, hydroxyzine) may be used for nocturnal pruritus to aid sleep, but long-term use is discouraged due to side effects.
• Stabilization (over days to weeks):
  • Wet-wrap therapy: After applying topical corticosteroids and emollients, apply wet bandages over the affected areas. Improves hydration, penetration of medications, and provides a physical barrier against scratching. Highly effective for severe flares, especially in children.
  • Topical Calcineurin Inhibitors (TCIs): Tacrolimus ointment (0.03% or 0.1%) or pimecrolimus cream (1%). Can be used on sensitive areas (face, eyelids, skin folds) where TCS are problematic. Slower onset than TCS but good for maintenance.
  • Management of Secondary Infection:
    • Topical Antibiotics: Mupirocin or fusidic acid for localized impetiginization.
    • Systemic Antibiotics: Oral antibiotics (e.g., cephalexin, dicloxacillin, clindamycin, doxycycline for MRSA suspected) for widespread bacterial infection, cellulitis, or non-responsive impetigo. Duration typically 7-10 days.
    • Antiviral Therapy: Oral acyclovir, valacyclovir, or famciclovir for eczema herpeticum (urgent initiation).
• Emergency (Rare, Severe Cases):
  • Systemic Corticosteroids: Oral prednisone (e.g., 0.5-1 mg/kg/day, max 60 mg/day for 5-7 days) may be used for severe, widespread, or acutely flaring eczema refractory to topical therapy, but should be tapered slowly to avoid rebound flares. Not for chronic management due to side effects.
  • Hospitalization: For severe, widespread flares, erythroderma, severe secondary infections, or eczema herpeticum requiring intravenous antiviral/antibiotic therapy or intensive supportive care.

Chronic Management

• Pharmacological:
  • Baseline Therapy:
    • Emollients/Moisturizers: Daily, generous application. Ointments are generally more effective than creams or lotions. Examples: petroleum jelly, mineral oil, ceramides, colloidal oatmeal formulations. Crucial for barrier repair.
  • Topical Anti-inflammatories:
    • Topical Corticosteroids (TCS): Used proactively 2-3 times/week on previously affected areas to prevent flares ("proactive therapy" or "weekend therapy"). Potency determined by severity and location.
    • Topical Calcineurin Inhibitors (TCIs): Tacrolimus ointment (0.03% for ages >2 years, 0.1% for ages >16 years) or Pimecrolimus cream (1% for ages >2 years). Used for sensitive areas, or as a corticosteroid-sparing agent for maintenance. Common side effect: transient burning/stinging.
    • Crisaborole Ointment 2%: A topical phosphodiesterase-4 (PDE4) inhibitor. Approved for mild-to-moderate AD in patients ≥3 months old. Applied BID. Good for sensitive areas.
  • Phototherapy:
    • Narrowband Ultraviolet B (NB-UVB): Effective for moderate-to-severe AD unresponsive to topical therapy. Usually 2-3 sessions per week. Requires specialized equipment and trained personnel.
    • UVA1: May be used for acute severe flares.
  • Systemic Therapies (for moderate-to-severe AD unresponsive to topicals and phototherapy):
    • Dupilumab: A monoclonal antibody targeting IL-4Rα (blocking IL-4 and IL-13 signaling). Approved for moderate-to-severe AD in patients ≥6 months old. Dosing: Varies by age/weight. For adults, typical initial dose 600 mg SC, then 300 mg SC every 2 weeks.
    • Tralokinumab: A monoclonal antibody targeting IL-13. Approved for moderate-to-severe AD in adults. Dosing: Initial 600 mg SC, then 300 mg SC every 2 weeks.
    • Janus Kinase (JAK) Inhibitors (oral):
      • Upadacitinib: (Selective JAK1 inhibitor) Approved for moderate-to-severe AD in adults and adolescents ≥12 years. Dosing: 15 mg once daily, may increase to 30 mg once daily for refractory cases.
      • Abrocitinib: (Selective JAK1 inhibitor) Approved for moderate-to-severe AD in adults and adolescents ≥12 years. Dosing: 100 mg once daily, may increase to 200 mg once daily.
      • Baricitinib: (JAK1/2 inhibitor) Approved for moderate-to-severe AD in adults. Dosing: 2-4 mg once daily.
      • Monitoring for JAK inhibitors: Requires baseline and periodic monitoring of CBC, lipids, and liver/kidney function. Associated with boxed warnings for serious infections, malignancy, major adverse cardiovascular events (MACE), and thrombosis.
    • Conventional Immunosuppressants: Used for severe refractory cases, often as bridge therapy or when biologics/JAK inhibitors are contraindicated/unavailable.
      • Cyclosporine: Most rapid onset, but nephrotoxic, hypertensive, and requires close monitoring (renal function, blood pressure). Dosing: 2.5-5 mg/kg/day, usually tapered.
      • Methotrexate: Slower onset, hepatotoxic, myelosuppressive. Dosing: 10-25 mg weekly. Requires folic acid supplementation and monitoring (liver enzymes, CBC).
      • Azathioprine: Slower onset, myelosuppressive, hepatotoxic. Requires TPMT enzyme testing before initiation. Dosing: 1-3 mg/kg/day.
      • Mycophenolate Mofetil: Less commonly used, similar efficacy to azathioprine.
• Non-pharmacological:
  • Skin Care Practices:
    • Bathing: Short, lukewarm baths (5-10 min) daily. Consider "soak and smear" technique (apply moisturizer immediately after bathing while skin is still damp). Bleach baths (1/4 to 1/2 cup household bleach in a full tub, 2-3 times/week) for reducing S. aureus colonization, but use with caution and proper dilution.
    • Gentle Cleansers: Use fragrance-free, soap-free cleansers.
    • Moisturize Frequently: Apply thick emollients liberally and often, especially within 3 minutes of bathing.
    • Clothing: Wear soft, breathable fabrics (cotton). Avoid wool and synthetic materials.
  • Trigger Avoidance: Identify and avoid known irritants (harsh soaps, detergents, perfumes, rough clothing) and allergens (pollen, dust mites, pet dander) if they are confirmed triggers.
  • Scratch Management: Keep fingernails short. Use cotton gloves at night. Address pruritus aggressively with appropriate therapies.
  • Stress Management: Stress reduction techniques (mindfulness, meditation, counseling) can help manage flares.
  • Education and Support: Educate patients and caregivers about the chronic nature of AD, proper skin care, medication use, and potential triggers. Support groups can be beneficial.
• Monitoring:
  • Regular follow-up: Assess disease severity (e.g., Eczema Area and Severity Index [EASI], SCORAD), treatment response, side effects, and adherence.
  • Adjust treatment: Step up or step down therapy based on disease activity.
  • Screen for complications: Infections, psychosocial impact.
  • Growth and development: In children.
  • Systemic therapy monitoring: Regular laboratory tests for patients on cyclosporine, methotrexate, azathioprine, or JAK inhibitors.

Treatment Algorithms

• First-Line (Mild AD):
  1. Patient Education: About chronic nature, skin barrier, triggers.
  2. Basic Skin Care: Daily gentle bathing, liberal use of emollients (multiple times daily, especially after bathing).
  3. Topical Corticosteroids (TCS): Low-potency (e.g., hydrocortisone 1%) for face/intertriginous areas, mid-potency (e.g., triamcinolone 0.1%) for body. Use until flare resolves, then proactive therapy (2-3 times/week) or switch to TCI for maintenance.
  4. Topical Calcineurin Inhibitors (TCIs): Tacrolimus 0.03%/0.1% or pimecrolimus 1% for sensitive areas or as steroid-sparing maintenance.
  5. Crisaborole Ointment 2%: Alternative topical anti-inflammatory for mild-to-moderate AD.
• Second-Line (Moderate AD, unresponsive to First-Line):
  1. Optimize First-Line: Ensure correct application, adherence, potency, and duration of topical agents.
  2. Higher Potency TCS: Judicious use of higher-potency TCS for short courses on thicker skin.
  3. Wet-wrap therapy: For localized severe flares.
  4. Phototherapy: NB-UVB 2-3 times/week.
  5. Consider Systemic Therapy Consult: If widespread moderate AD impacting QoL.
• Refractory Cases (Severe AD, unresponsive to Second-Line):
  1. Re-evaluate Diagnosis: Consider alternative conditions or comorbidities.
  2. Address Triggers/Complications: Screen for contact allergens (patch testing), food allergies (if suspected), and infections.
  3. Systemic Therapies:
     • Biologics: Dupilumab (first-line biologic option), Tralokinumab. Generally preferred over conventional immunosuppressants due to better safety profile and targeted action.
     • JAK Inhibitors: Upadacitinib, Abrocitinib, Baricitinib. Oral systemic options with rapid onset. Careful patient selection and monitoring due to safety warnings.
     • Conventional Immunosuppressants: Cyclosporine (fastest onset, useful for acute severe flares), Methotrexate, Azathioprine, Mycophenolate Mofetil. Reserved for cases where biologics/JAK inhibitors are not suitable or available, given their broader side effect profiles.
  4. Multidisciplinary Approach: Collaborate with dermatologists, allergists, mental health professionals, and dieticians.

Complications

• Common:
  • Secondary Bacterial Infections: Most commonly Staphylococcus aureus (impetigo, folliculitis, cellulitis). Yellow crusting, pustules, rapidly spreading redness. Risk of MRSA.
  • Secondary Viral Infections:
    • Eczema Herpeticum (EH): Widespread dissemination of Herpes Simplex Virus (HSV) in eczematous skin, presenting as monomorphic, "punched-out" erosions, vesicles, or hemorrhagic crusts. Medical emergency.
    • Molluscum Contagiosum: Viral infection causing small, pearly, umbilicated papules.
    • Warts (Verruca Vulgaris): Due to human papillomavirus (HPV).
  • Secondary Fungal Infections: Less common, but dermatophyte infections (tinea) can mimic eczema.
  • Lichenification: Skin thickening due to chronic rubbing/scratching.
  • Post-inflammatory Hyperpigmentation/Hypopigmentation: Common, especially in skin of color, can be cosmetically distressing.
• Serious:
  • Erythroderma (Exfoliative Dermatitis): Generalized redness and scaling covering >90% of the body surface area. Can lead to thermoregulatory dysfunction, fluid/electrolyte imbalance, high-output cardiac failure, and requires hospitalization.
  • Sepsis: From severe bacterial superinfection.
  • Ocular Complications: Atopic keratoconjunctivitis, anterior blepharitis, cataracts, retinal detachment (rare). Especially with chronic facial eczema or long-term high-potency topical steroid use around eyes.
  • Growth Retardation: In severe, poorly controlled pediatric AD.
• Long-term:
  • Psychosocial Impact: Sleep disturbance, anxiety, depression, social isolation, poor self-esteem, bullying (in children). Significant burden on quality of life for patients and families.
  • Hand Eczema: Chronic, debilitating condition, often occupational, difficult to treat.
  • Increased Risk of Other Atopic Diseases: Individuals with AD are at higher risk for developing asthma, allergic rhinitis, and food allergies (the "atopic march").
  • Chronic Pain: From fissures, excoriations, or neuropathy from chronic pruritus.
  • Skin Thinning/Striae: From prolonged or inappropriate use of high-potency topical corticosteroids.

Prognosis

• Factors:
  • Age of onset: Earlier onset typically associated with a higher likelihood of persistence.
  • Severity: More severe disease in childhood is more likely to persist into adulthood.
  • Atopic Comorbidities: Presence of asthma or allergic rhinitis is associated with longer persistence.
  • Family history: Strong family history of atopy.
  • Filaggrin gene mutations: Associated with more severe and persistent disease.
• Survival: Eczema is not directly life-threatening, but severe disease and its complications (e.g., severe infections, erythroderma complications) can lead to significant morbidity and rarely, mortality.
• Quality of Life: Significantly impacted by chronic pruritus, sleep disturbance, pain, cosmetic concerns, and psychosocial burden. Patients often report similar QoL impairment as those with diabetes or cardiovascular disease. Impact on family members and caregivers is also substantial.
  • Children: Impaired school performance, social development.
  • Adults: Impaired work productivity, relationships.

Prevention

• Primary: Preventing the initial occurrence of AD.
  • Emollient Use in High-Risk Infants: Regular application of moisturizers from birth (at least daily for the first 6-8 months) in infants with a family history of AD/atopy has shown some evidence of reducing the incidence of AD.
  • Avoid Irritants: Use mild, pH-neutral cleansers; avoid harsh soaps and detergents; dress infants in soft, breathable fabrics.
  • Environmental Control: Reduce exposure to house dust mites (e.g., mattress covers, frequent washing of bedding) and pet dander if specifically identified as a trigger.
  • Dietary Interventions: Limited evidence for dietary restrictions in pregnant/lactating women or infants to prevent AD. Current guidelines generally do not recommend routine allergen avoidance diets for prevention.
• Secondary: Early detection and intervention to prevent progression or severity.
  • Early Recognition and Treatment: Prompt and effective management of initial symptoms can prevent progression to chronic, severe disease.
  • Consistent Basic Skin Care: Emphasize daily moisturizing and gentle skin care to maintain skin barrier function even when symptoms are minimal.
  • Proactive Topical Therapy: Regularly applying topical corticosteroids or calcineurin inhibitors to previously affected areas (e.g., 2-3 times/week) can prevent flares and reduce overall medication burden.
• Tertiary: Preventing complications and managing chronic disease effectively.
  • Adherence to Treatment Plan: Emphasize the importance of consistent use of emollients and prescribed medications.
  • Trigger Identification and Avoidance: Help patients identify and manage their specific triggers.
  • Early Intervention for Flares: Teach patients to recognize early signs of a flare and initiate appropriate acute treatment to prevent escalation.
  • Management of Pruritus: Address itch effectively to break the itch-scratch cycle.
  • Psychosocial Support: Refer to counseling or support groups as needed to address mental health impacts.
  • Infection Control: Educate on signs of infection and importance of prompt treatment.

Special Populations

• Pediatric:
  • Infantile Eczema (0-2 years): Predominantly on face, scalp, extensor surfaces. Wet, weeping lesions. Caregivers require extensive education on skin care, bathing, and safe use of topical steroids (low-potency hydrocortisone 1% or 2.5% is common).
  • Childhood Eczema (2-12 years): Classic flexural distribution (antecubital, popliteal fossae). Lichenification more common. Higher potency topical steroids may be needed cautiously. Dupilumab approved for children ≥6 months. JAK inhibitors approved for adolescents ≥12 years.
  • Growth and Development: Monitor growth. Uncontrolled severe AD can rarely impact growth.
  • Food Allergies: More common in severe infantile AD; consider evaluation if specific food triggers are suspected based on history.
• Geriatric:
  • Asteatotic Eczema: Very common due to age-related skin dryness (xerosis). Focus on aggressive moisturization, humidification.
  • Nummular Eczema: Often presents in older adults.
  • Polypharmacy/Comorbidities: Consider drug interactions and systemic side effects of treatments. Renal/hepatic impairment may necessitate dose adjustments for systemic agents. Skin may be thinner and more fragile, requiring careful use of topical steroids.
• Pregnancy:
  • Topical Corticosteroids: Generally considered safe, especially low-to-mid potency, but high-potency should be used cautiously.
  • Topical Calcineurin Inhibitors: Limited data, generally considered low risk but prefer TCS as first line.
  • Phototherapy (NB-UVB): Considered safe and effective.
  • Systemic Agents:
    • Oral Corticosteroids: Use with caution, lowest effective dose for shortest duration. Risk of oral cleft in first trimester (small), gestational diabetes, preeclampsia.
    • Cyclosporine: Considered an option for severe refractory AD in pregnancy when benefits outweigh risks; known to be used in transplant patients.
    • Dupilumab: Data from post-marketing surveillance and pregnancy registry suggest no increased risk of major birth defects or miscarriage. May be considered if needed for severe AD.
    • JAK Inhibitors/Methotrexate/Mycophenolate Mofetil/Azathioprine: Generally contraindicated or not recommended due to safety concerns and potential teratogenicity.
  • Breastfeeding: Most topical agents are compatible. Discuss specific systemic agent safety with patient.
• Comorbidities:
  • Allergic Rhinitis, Asthma: Common comorbidities (atopic march). Coordinated care with allergists/pulmonologists. Systemic treatments like dupilumab can improve both AD and asthma/rhinitis.
  • Infections: Increased susceptibility to bacterial, viral (HSV, vaccinia), and fungal infections.
  • Mental Health Disorders: High rates of anxiety, depression, ADHD. Screen patients and provide appropriate referrals.
  • Sleep Disorders: Directly related to pruritus. Address sleep hygiene, consider sedating antihistamines at night short-term, optimize AD control.
  • Metabolic Syndrome: Emerging evidence suggests an association between severe AD and increased risk of obesity, dyslipidemia, hypertension, and diabetes.

Clinical Pearls

• Diagnostic:
  • "If it's not itchy, it's not eczema." Pruritus is the cardinal symptom.
  • Always consider secondary infection, especially if lesions are suddenly weeping, pustular, or crusted, or if the patient develops fever/malaise.
  • A sudden change in morphology or distribution, or failure to respond to appropriate treatment, warrants reconsideration of the diagnosis (e.g., scabies, psoriasis, cutaneous lymphoma).
  • In adults with chronic, localized, intensely itchy eczema, especially on hands, consider allergic contact dermatitis and patch testing.
• Treatment:
  • Emollients are foundational: No pharmacological treatment will be fully effective without consistent and liberal emollient use. "Moisturize, moisturize, moisturize."
  • Fear of topical steroids is common (steroid phobia): Educate patients on appropriate use, potency, and potential side effects vs. benefits. Explain that proper use can prevent flares and reduce the need for more potent therapies.
  • "Soak and smear": Bathing for 5-10 minutes in lukewarm water, then immediately applying moisturizer (and TCS if prescribed) while skin is still damp, is highly effective.
  • Proactive therapy: Applying topical anti-inflammatories (TCS or TCIs) 2-3 times a week to previously affected areas, even when clear, can prevent flares and reduce overall disease activity.
  • Itch-scratch cycle: Breaking this cycle is key. Aggressive itch control and prevention of scratching are critical.
  • Manage expectations: Eczema is chronic and relapsing. The goal is control, not cure.
• Pitfalls:
  • Under-treatment: Using insufficient potency or frequency of topical corticosteroids for the severity of eczema.
  • Over-treatment: Prolonged use of high-potency topical corticosteroids on thin skin (face, folds) leading to atrophy, telangiectasias, or striae.
  • Missing secondary infections: Delaying antibiotic/antiviral treatment can lead to worse outcomes, especially for eczema herpeticum.
  • Ignoring psychosocial impact: Not addressing the profound effect of eczema on quality of life, mental health, and sleep.
  • Dietary restrictions without evidence: Unnecessary or overly restrictive diets, especially in children, can lead to nutritional deficiencies without proven benefit for most AD.

Recent Updates

• Guidelines:
  • Multiple national and international guidelines (e.g., American Academy of Dermatology, European Academy of Dermatology and Venereology) have been updated to incorporate newer systemic therapies.
  • Emphasis on shared decision-making and patient-centered care.
  • Increased focus on the importance of emollients and proactive topical therapy.
• Evidence:
  • Biologics: Continued robust evidence for dupilumab, tralokinumab, and lebrikizumab (an investigational IL-13 inhibitor) demonstrating significant efficacy and favorable safety profiles for moderate-to-severe AD across various age groups.
  • JAK Inhibitors: Strong evidence for oral JAK inhibitors (upadacitinib, abrocitinib, baricitinib) providing rapid and substantial improvements in pruritus and skin clearance in moderate-to-severe AD, but with important safety considerations (boxed warnings for serious infections, MACE, thrombosis, malignancy).
  • Topical Therapies: Crisaborole and ruxolitinib cream (topical JAK inhibitor, approved for mild-to-moderate AD in patients ≥12 years) have expanded topical treatment options beyond corticosteroids and calcineurin inhibitors.
  • Skin Microbiome: Growing research into the role of skin microbiome dysbiosis in AD pathogenesis and potential therapeutic targets (e.g., live bacterial therapeutics).
  • Pruritus Research: Deeper understanding of the neuro-immune mechanisms underlying chronic itch in AD, leading to development of targeted anti-pruritic agents (e.g., IL-31 receptor antagonists).
• Controversies:
  • Long-term safety of JAK Inhibitors: Ongoing real-world data collection and post-marketing surveillance are crucial to further characterize long-term safety profiles, especially regarding serious adverse events (MACE, thrombosis, malignancy) compared to other systemic agents.
  • Role of Food Allergy in AD: While certain food allergies can exacerbate AD in a subset of children, routine dietary restrictions are not recommended for all AD patients, and appropriate diagnostic work-up for food allergy is essential to avoid unnecessary dietary avoidance.
  • Early Intervention for AD: Debate on whether aggressive early intervention can alter the "atopic march" and prevent the development of asthma and allergic rhinitis.

Key References

• Guidelines:
  • American Academy of Dermatology (AAD) Guidelines of Care for the Management of Atopic Dermatitis. (Regularly updated, consult AAD website).
  • European Academy of Dermatology and Venereology (EADV) Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis). (Published periodically in JEADV).
  • National Institute for Health and Care Excellence (NICE) Clinical Guideline [CG57]: Atopic eczema in children and young people. (UK-based, comprehensive guidance).
  • World Allergy Organization (WAO) Guidelines for the Assessment and Management of Atopic Dermatitis.
• Studies:
  • Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-7. (Original diagnostic criteria).
  • Williams HC, et al. Diagnostic criteria for atopic dermatitis: an international consensus statement. Br J Dermatol. 1999;141(6):1037-43. (UK Working Party Criteria).
  • Registrational Trials for Biologics & JAK Inhibitors: LIBERTY AD (Dupilumab), ECZTRA (Baricitinib), ADMIRAL (Abrocitinib), Measure Up/Up Next (Upadacitinib), ECZTRA (Tralokinumab). (Access through PubMed or drug manufacturer websites).
  • Long-term Safety Studies: Post-marketing surveillance and extension studies for newer systemic agents.
• Reviews:
  • Reviews published in major dermatology journals (e.g., Journal of the American Academy of Dermatology, British Journal of Dermatology, Journal of Allergy and Clinical Immunology, The Lancet).
  • Cochrane Reviews on specific eczema interventions (e.g., emollients, topical corticosteroids, psychological interventions).